Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENT-03 phase 2a study in active cutaneous lupus erythematosus
2024-520098-12-00Phase 2Authorised
- Sponsor
- Ventus Therapeutics
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of VENT-03 in cutaneous lupus erythematosus (CLE) (3 arms), sponsored by Ventus Therapeutics. Primary endpoint: Percent change from baseline in the interferon gene signature in skin at Day 28. Planned start Feb 2026; status: authorised.
02
Drugs
VENT-03
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on 2024-520098-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520098-12-00.